What is the recommended use and dosage of Oseltamivir (Tamiflu) for influenza?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 27, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Recommended Use and Dosage of Oseltamivir (Tamiflu) for Influenza

Oseltamivir is recommended for treatment of influenza in patients when started within 48 hours of symptom onset, with a standard adult dosage of 75 mg twice daily for 5 days, and weight-based dosing for children. 1, 2

Adult Dosing

  • For treatment of influenza: 75 mg twice daily for 5 days 1, 2
  • For prophylaxis of influenza: 75 mg once daily for at least 10 days following close contact with an infected individual, and up to 6 weeks during a community outbreak 1, 2
  • No dosage adjustment needed based on age alone for elderly patients 1

Pediatric Dosing

Children ≥1 year (treatment for 5 days):

  • ≤15 kg: 30 mg twice daily 1
  • 15-23 kg: 45 mg twice daily 1

  • 23-40 kg: 60 mg twice daily 1

  • 40 kg: 75 mg twice daily 1

Children ≥1 year (prophylaxis):

  • Same weight-based dosing as treatment, but administered once daily instead of twice daily 1

Infants <1 year:

  • 3 mg/kg twice daily for treatment 1
  • Not recommended for prophylaxis in infants <3 months unless situation is critical 1
  • For infants 3-11 months: 3 mg/kg once daily for prophylaxis 1

Special Populations

Renal Impairment

  • For patients with creatinine clearance 10-30 mL/min: reduce treatment dosage to 75 mg once daily and prophylaxis dosage to 75 mg every other day 1, 3
  • Not recommended for patients with end-stage renal disease not undergoing dialysis 2

Timing of Administration

  • Treatment should be initiated within 48 hours of symptom onset for maximum effectiveness 1, 4
  • Earlier initiation (within 24 hours) results in greater reduction of symptom duration 4

Clinical Benefits

  • Reduces duration of influenza symptoms by approximately 29-36 hours (25-30%) in otherwise healthy adults 5, 4
  • In high-risk populations (those with chronic respiratory or cardiac diseases), oseltamivir reduces symptom duration by 36.8% and severity by 43.1% 6
  • Reduces incidence of secondary complications and antibiotic use in both healthy and high-risk patients 5, 6

Formulations and Administration

  • Available as capsules (30 mg, 45 mg, and 75 mg) and oral suspension (6 mg/mL) 3, 2
  • Can be taken with or without food, though taking with food may improve gastrointestinal tolerability 3, 2
  • If commercial oral suspension is unavailable, capsules can be opened and mixed with sweetened liquid 1

Common Side Effects and Precautions

  • Most common adverse events are nausea and vomiting, which are generally mild and transient 5, 7
  • Gastrointestinal events are less likely when oseltamivir is taken with food 5
  • No benefit has been demonstrated for double-dose oseltamivir (150 mg twice daily) compared to standard dose in patients with severe influenza 8

Prophylaxis Considerations

  • Protective efficacy of 74-87% when used for seasonal prophylaxis 7
  • For institutional outbreaks, chemoprophylaxis should be administered to all eligible residents for a minimum of 2 weeks, and continued until approximately 7-10 days after illness onset in the last patient 1

Oseltamivir remains a key antiviral medication for both treatment and prophylaxis of influenza, with established efficacy in reducing symptom duration and complications when initiated promptly after symptom onset.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.